| Species |
Human |
| Protein Construction |
BMP-2 (Gln283-Arg396)
Accession # P12643 |
|
| Purity |
> 95% as analyzed by SDS-PAGE
> 95% as analyzed by HPLC |
| Endotoxin Level |
< 1 EU/μg of protein by gel clotting method |
| Biological Activity |
Assay #1: Measured by its ability to induce alkaline phosphatase production by ATDC-5 Cells. The ED50 for this effect is typically 0.07-0.2 μg/ml.Assay #2: Measured by its ability to induce alkaline phosphatase production by C2C12 cells. The ED50 for this effect is typically 0.2-1 μg/ml. |
| Expression System |
E. coli |
| Apparent Molecular Weight |
~26 kDa, on SDS-PAGE under non-reducing conditions. |
| Formulation |
Lyophilized after extensive dialysis against 50 mM acetic acid. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in 20 mM AcOH or 5 mM HCl up to 100 μg/ml. |
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
Biological Activity
BMP-2, Human (Cat. No. Z02913) induce alkaline phosphatase production by ATDC5 cells. The ED50 for this effect is typically 0.07- 0.20 ug/mL.
Biological Activity
BMP-2, Human (Cat. No. Z02913) induce alkaline phosphatase production by C2C12 cells. The ED50 for this effect is typically 0.20- 1.00 ug/mL.
GenScript product showed better activity compared to competitor P
2 μg of BMP-2, Human (Cat. No. Z02913) was resolved with SDS-PAGE under reducing (R) and non-reducing (N) conditions and visualized by Coomassie Blue staining.
Biological Activity
BMP-2, Human (Cat. No. Z02913) induce alkaline phosphatase production by C2C12 cells. The ED50 for this effect is typically 0.10-0.80 ug/mL.
Biological Activity
BMP-2, Human (Cat. No. Z02913) induce alkaline phosphatase production by ATDC5 cells. The ED50 for this effect is typically 0.07-0.20 ug/mL.
| Target Background |
Human Bone Morphogenetic Protein-2 (BMP-2) is a bone-growth regulatory factor and belongs to the transforming growth factor-beta (TGF-beta) superfamily. Human Bone Morphogenetic Protein-2 (BMP-2) is synthesized as large precursor molecule (Met1-Arg396, with a signal peptide from Met1 to Gly23), propeptide (Leu24-Arg282) of which is cleaved by PCSK5 (Proprotein Convertase Subtilisin/Kexin type 5). The active form consists of a dimer of two identical proteins which are linked by a disulfide bond at Cys360. It plays an important role in the development of bone and cartilage, cardiac cell differentiation and epithelial to mesenchymal transition. It is also involved in the hedgehog pathway, TGF-beta signaling pathway, and in cytokine-cytokine receptor interaction. |
| Synonyms |
BMP-2; BMP2A; Bone morphogenetic protein 2; BMP-2A; BMP2 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
